Other Events ·
On September 10, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration cleared its…
PRLDPrelude Therapeutics Inc
On September 10, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for PRT13722, a first-in-class oral KAT6A selective degrader. The company intends to initiate a Phase 1 study in patients with HR+/HER2- breast cancer during the fourth quarter of 2026. This regulatory milestone advances Prelude's precision oncology pipeline and supports its strategy to develop targeted therapies for high-unmet-need malignancies. Prelude Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer medicines using targeted protein degradation technologies.